Nurix, Inc., a San Francisco, California-based company that discovers and develops therapies that modulate the ubiquitin proteasome system (UPS), raised $25.1m in Series B financing.
Led by Mark A. Goldsmith, M.D., Ph.D., partner of Third Rock Ventures and interim chief executive officer, and Mark Gallop, Ph.D., chief scientific officer, Nurix is a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS). The UPS is a regulatory pathway that directs protein degradation, a function vital to the healthy life of a cell, and presents therapeutic opportunities in multiple disease areas, including oncology.
The founding team of the company includes:
– John Kuriyan, Ph.D., Howard Hughes Medical Institute investigator and professor of molecular and cell biology and of chemistry, University of California, Berkeley, an expert in the structural dynamics of ubiquitin ligases and other signaling complexes;
– Michael Rapé, Ph.D., Howard Hughes Medical Institute investigator and professor of cell and developmental biology, University of California, Berkeley, a leader in the biology of ubiquitin-dependent cell cycle progression and carcinogenesis; and,
Arthur Weiss, M.D., Ph.D., Howard Hughes Medical Institute investigator and Ephraim P. Engleman distinguished professor, University of California San Francisco, a pioneer in immunology and signal transduction.